SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Myriad Genetics, Inc. (MYGN)
An SI Board Since August 1996
Posts SubjectMarks Bans Symbol
2355 65 0 MYGN
Emcee:  s myers Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1580One that I'm proud of? I risk tempting Miljenko here........ :-) Agouron.scaram(o)uche-8/3/2005
1579MYGN hasn't updated the clinical trials record yet. clinicaltrials.gov &quLee39-8/3/2005
1578Great thread guys..what's a really good drug development story?, one that yozeta1961-8/3/2005
1577Centoxin is a particularly ugly story. The trial was stopped after it was obserscaram(o)uche-8/2/2005
1576How about Centoxin (spelling?)? JonRobohogs-8/2/2005
1575I’ll bet Hemopure wins handily if the metric is a wasted <i>money</i>DewDiligence_on_SI-8/2/2005
1574On the other hand, it took Scios years and years (close to 20???) to develop nesrkrw-8/2/2005
1573A little nostalgia for you then...from 1995 <i>SEATTLE, Oct. 26 /PRNewswikeokalani'nui-8/2/2005
1572one of my faves...... pixykine.scaram(o)uche-8/2/2005
1571Biopure has been at it for over 20 years with hemopure. I think OSI finally kilrkrw-8/2/2005
1570>> Maximine? << Yeah, ya know, maybe it's no coincidence that Mscaram(o)uche-8/2/2005
1569groan....... my, what a pretty list. ;-) Aptosin....... the only one thatscaram(o)uche-8/2/2005
1568"the therafectin of this decade" Too funny, but not (yet) fair! THATkeokalani'nui-8/2/2005
1567So, R-flurbiprofen becomes the therafectin of this decade, and Peter Meldrum winscaram(o)uche-8/2/2005
1566Yes. And they also snuck in "food"....... <i>and maintaining scaram(o)uche-8/2/2005
1565Can I have some clarifications ? The original Ph 3 started with 2 doses, >&Lee39-8/2/2005
1564Peter Meldrum: In 1996, your SALARY and bonus for were $175K and $90K, respectiscaram(o)uche-8/2/2005
1563>> said Adrian Hobden, Ph.D. << Hobden doesn't IMO sound or reascaram(o)uche-8/2/2005
1562>> If true, then there has been a reg Fd violation. << Myriad Genetscaram(o)uche-8/2/2005
1561Moral low ground Nicola McCarthy The European Patent Office (EPO) has upheld aIcebrg-8/1/2005
1560PHARMACEUTICAL METHODS, DOSING REGIMES AND DOSAGE FORMS FOR THE TREATMENT OF ALZscaram(o)uche-7/31/2005
1559Peter Meldrum: Maria B. on CNBC said, following today's Chrysler bit, that scaram(o)uche-7/28/2005
1558Prolexys Pharmaceuticals Joins International Consortium to Develop New Tuberculoscaram(o)uche-7/28/2005
1557Peptides. 2005 Aug;26(8):1383-93. Epub 2005 Apr 21. Effect of neurokinin-1 recscaram(o)uche-7/28/2005
1556Biol Psychiatry. 2005 Jul 15;58(2):132-42. Cerebral Blood Flow Changes After Tscaram(o)uche-7/27/2005
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News